Energenesis Biomedical CO.,LTD. (TPE:6657)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
47.00
+1.75 (3.87%)
Feb 11, 2026, 1:30 PM CST
Market Cap4.01B +4.8%
Revenue (ttm)7.46M +0.9%
Net Income-243.50M
EPS-2.85
Shares Out88.66M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume382,648
Average Volume1,028,675
Open45.20
Previous Close45.25
Day's Range45.20 - 47.60
52-Week Range39.75 - 85.60
Beta0.47
RSI50.11
Earnings DateFeb 26, 2026

About TPE:6657

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERG... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 35
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6657
Full Company Profile

Financial Performance

In 2024, TPE:6657's revenue was 7.75 million, an increase of 8.26% compared to the previous year's 7.16 million. Losses were -231.08 million, -11.25% less than in 2023.

Financial Statements